drugset / Trial / NCT02268435

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

NCT02268435

Phase 1 Withdrawn Asan Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to determine the recommended dose of combination of dovitinib and imatinib in phase I study.

Timeline

Start
2015-03
Primary completion
2016-08
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule
Subject Imatinib Small molecule